NYSEAMERICAN:OCX

OncoCyte Stock Forecast, Price & News

$3.42

-0.15 (-4.20 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.30

Now: $3.42▼

$3.62

50-Day Range

$2.12

MA: $2.38▼

$2.63

52-Week Range

$1.15

Now: $3.42▼

$3.68

Volume869,898 shs

Average Volume1.25 million shs

Market Capitalization$230.00 million

P/E RatioN/A

Dividend YieldN/A

Beta2.23

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.

MarketRank^™

Overall MarketRank^™

1.74 out of 5 stars

Medical Sector

147th out of 1,557 stocks

Diagnostic Substances Industry

3rd out of 28 stocks

4.4 Analyst's Opinion

Consensus Rating
OncoCyte has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.29, OncoCyte has a forecasted upside of 25.3% from its current price of $3.42.
Amount of Analyst Coverage
OncoCyte has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
OncoCyte has received 176 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
OncoCyte has received 140 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
OncoCyte has received 55.70% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote “Outperform” if you believe OCX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
OncoCyte does not currently pay a dividend.
Dividend Growth
OncoCyte does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OncoCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,371.00 in company stock.
Percentage Held by Insiders
Only 5.64% of the stock of OncoCyte is held by insiders.
Percentage Held by Institutions
46.53% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for OncoCyte are expected to grow in the coming year, from ($0.46) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OncoCyte is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OncoCyte is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OncoCyte has a P/B Ratio of 5.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Diagnostic substances

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:OCX

Previous SymbolAMEX:OCX

CUSIPN/A

CIK1642380

Webwww.oncocyte.com

Phone(510) 775-0515

Employees33

Debt

Debt-to-Equity Ratio0.17

Current Ratio1.35

Quick Ratio1.35

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.59 per share

Price / Book5.80

Profitability

EPS (Most Recent Fiscal Year)($0.44)

Net Income$-22,430,000.00

Net MarginsN/A

Return on Equity-89.14%

Return on Assets-57.26%

Miscellaneous

Outstanding Shares67,251,000

Market Cap$230.00 million

Next Earnings Date3/24/2021 (Estimated)

OptionableNot Optionable

$3.42

-0.15 (-4.20 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

How has OncoCyte's stock been impacted by COVID-19?

OncoCyte's stock was trading at $2.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OCX shares have increased by 59.8% and is now trading at $3.42.
View which stocks have been most impacted by COVID-19.

Is OncoCyte a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OncoCyte stock.
View analyst ratings for OncoCyte or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than OncoCyte?

Wall Street analysts have given OncoCyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OncoCyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for OncoCyte.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NYSEAMERICAN:OCX) posted its quarterly earnings results on Thursday, November, 12th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The biotechnology company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.62 million.
View OncoCyte's earnings history.

What price target have analysts set for OCX?

7 equities research analysts have issued twelve-month price objectives for OncoCyte's shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate OncoCyte's share price to reach $4.29 in the next year. This suggests a possible upside of 25.3% from the stock's current price.
View analysts' price targets for OncoCyte or view Wall Street analyst' top-rated stocks.

Are investors shorting OncoCyte?

OncoCyte saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 2,220,000 shares, a drop of 14.3% from the December 15th total of 2,590,000 shares. Based on an average daily trading volume, of 2,090,000 shares, the short-interest ratio is currently 1.1 days.
View OncoCyte's Short Interest.

Who are some of OncoCyte's key competitors?

Some companies that are related to OncoCyte include Celldex Therapeutics (CLDX), Aspira Women's Health (AWH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB), ImmuCell (ICCC), StageZero Life Sciences (GNWSF), ARCA biopharma (ABIO), Achieve Life Sciences (ACHV), StageZero Life Sciences (GNWSD), Akers Biosciences (AKER) and Response Genetics (RGDXQ).
View all of OCX's competitors.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA), BioTime (BTX), Fulcrum Therapeutics (FULC), Alnylam Pharmaceuticals (ALNY), VIVUS (VVUS), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), AcelRx Pharmaceuticals (ACRX), Agile Therapeutics (AGRX) and Aldeyra Therapeutics (ALDX).

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:

Mr. Ronald A. Andrews Jr., CEO, Pres & Director (Age 60, Pay $312.5k)
Mr. Mitchell S. Levine, Chief Financial Officer
Dr. Lyndal K. Hesterberg Ph.D., Chief Scientific Officer
Mr. William Annett, Advisor (Age 66, Pay $673.33k)
Mr. Albert P. Parker II, COO & Sec.
Mr. Tony T. Kalajian CPA, M.B.A., Sr. VP & Chief Accounting Officer
Ms. Padma Sundar, Sr. VP of Commercial
Dr. Douglas T. Ross M.D., Ph.D., Chief Medical Officer
Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 67)
Ms. Sara Riordan, Director of Medical Education

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $3.42.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $230.00 million. The biotechnology company earns $-22,430,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. OncoCyte employs 33 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here